Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies

References

• Richardson PG, Barlogie B, Berenson J, et al A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609–2617.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Barlogie B, Berenson J, et al A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165–172.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487–2498.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906–917.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster M, et al Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557–3560.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Briemberg H, Jagannath S, et al Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113–3120.
   PubMed Web of Science ®Google Scholar
• Chaudhry V, Cornblath DR, Polydefkis M, Ferguson A, Borrello I. Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst 2008;13:275–282.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008;112:1593–1599.
   PubMed Web of Science ®Google Scholar
• Gilardini A, Marmiroli P, Cavaletti G. Proteasome inhibition: a promising strategy for treating cancer, but what about neurotoxicity? Curr Med Chem 2008;15:3025–3035.
   PubMed Web of Science ®Google Scholar
• Badros A, Goloubeva O, Dalal JS, et al Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007;110:1042–1049.
   PubMed Web of Science ®Google Scholar
• Kannarkat G, Lasher EE, Schiff D. Neurologic complications of chemotherapy agents. Curr Opin Neurol 2007;20:719–725.
   PubMed Web of Science ®Google Scholar
• Tariman JD, Love G, McCullagh E, Sandifer S. Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. Clin J Oncol Nurs 2008;12:29–36.
   PubMed Web of Science ®Google Scholar
• Meregalli C, Canta A, Carozzi VA, et al Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. Eur J Pain 2010;14:343–350.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 2009;144:895–903.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Durie BG, Wolf J, et al Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005;129:776–783.
   PubMed Web of Science ®Google Scholar
• Freimann H, Calderoni A, Cornu P, Olie R. Daily practice use of bortezomib in relapsed/refractory multiple myeloma: safety/efficacy results of a compassionate use program in Switzerland. Swiss Med Wkly 2007;137:317–322.
   PubMed Web of Science ®Google Scholar
• Colvin LA, Johnson PR, Mitchell R, Fleetwood-Walker SM, Fallon M. From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol. J Clin Oncol 2008;26:4519–4520.
   PubMed Web of Science ®Google Scholar
• Prommer EE. Topical analgesic combinations for bortezomib neuropathy. J Pain Symptom Manage 2009;37:e3–e5.
   PubMedGoogle Scholar
• Stubblefield MD, Slovin S, MacGregor-Cortelli B, et al An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib. Clin Oncol (R Coll Radiol) 2006;18:410–418.
   PubMed Web of Science ®Google Scholar
• Gupta S, Pagliuca A, Devereux S, Mufti GJ, Schey S. Life-threatening motor neurotoxicity in association with bortezomib. Haematologica 2006;91:1001.
   PubMed Web of Science ®Google Scholar
• Ravaglia S, Corso A, Piccolo G, et al Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin Neurophysiol 2008;119:2507–2512.
   PubMed Web of Science ®Google Scholar
• Caravita T, Petrucci MT, Spagnoli A, et al Neuropathy in multiple myeloma patients treated with bortezomib: a multicenter experience. Blood 2007;110(Suppl. 1): (Abstract 4823).
   Google Scholar
• Berenson JR, Jagannath S, Barlogie B, et al Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 2005;104:2141–2148.
   PubMed Web of Science ®Google Scholar
• Corso A, Mangiacavalli S, Varettoni M, Pascutto C, Zappasodi P, Lazzarino M. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients. Leuk Res 2010;34:471–474.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Hernandez JM, Hernandez MT, et al Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006;108:2165–2172.
   PubMed Web of Science ®Google Scholar
• Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 1998;9:739–744.
   PubMed Web of Science ®Google Scholar
• Chen CI, Kouroukis CT, White D, et al Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1570–1575.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Oriol A, Martinez J, et al A prospective, multicenter, randomized, trial of bortezomib/melphalan/prednisone (VMP) versus bortezomib/thaldiomide/prednisone (VTP) as induction therapy followed by maintenance treatment with bortezomib/thalidomide (VT) versus bortezomib/prednisone (VP) in elderly untreated patients with mutiple myeloma older than 65 years. Blood 2009;114(Suppl. 1): 3.
   Google Scholar
• Palumbo A, Bringhen S, Rossi D, et al Bortezomib, melphalan, prednisone and thalidomide (VMPT) followed my mantenance with bortezomib and thalidomide for initial treatment of elderly multiple myeloma patients. Blood 2009;114(Suppl. 1):128.
   PubMed Web of Science ®Google Scholar
• Lanzani F, Mattavelli L, Frigeni B, et al Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity. J Peripher Nerv Syst 2008;13:267–274.
   PubMed Web of Science ®Google Scholar
• Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006;24:4507–4514.
   PubMed Web of Science ®Google Scholar
• List A, Dewald G, Bennett J, et al Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456–1465.
   PubMed Web of Science ®Google Scholar
• Park SB, Krishnan AV, Lin CS, Goldstein D, Friedlander M, Kiernan MC. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 2008;15:3081–3094.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Blood E, Mitsiades CS, et al A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458–3464.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Richardson PG, Barlogie B, et al Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006;91:929–934.
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Mitsiades NS, McMullan CJ, et al Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006;107:1092–1100.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Chanan-Khan A, Lonial S, et al Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: final results of a phase I/II study. J Clin Oncol 2009;27(Suppl.): Abstract 8503.
   Google Scholar
• Zhong Z, Simmons J, Timmermans P. Prevention and treatment of bortezomib-induced peripheral neuropathy by the Hsp90 inhibitor tanespimycin (KOS-953) in the rat. Presented at 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. October 2008. Geneva, Switzerland.
   Google Scholar
• Waza M, Adachi H, Katsuno M, et al Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein. J Mol Med 2006;84:635–646.
   PubMed Web of Science ®Google Scholar
• Brown IR. Heat shock proteins and protection of the nervous system. Ann NY Acad Sci 2007;1113:147–158.
   PubMed Web of Science ®Google Scholar
• Kelly S, Yenari MA. Neuroprotection: heat shock proteins. Curr Med Res Opin 2002;18(Suppl. 2):s55–s60.
   PubMedGoogle Scholar
• Yenari MA. Heat shock proteins and neuroprotection. In: Alzheimer C, editor. Molecular and cellular biology of neuroprotection in the CNS. New York: Landes Bioscience, Kluwer Academic/Plenum Publishers; 2002. pp 281–300.
   Google Scholar
• Chauhan D, Singh A, Brahmandam M, et al Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 2008;111:1654–1664.
   PubMed Web of Science ®Google Scholar
• Kuhn DJ, Chen Q, Voorhees PM, et al Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007;110:3281–3290.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Bergsagel PL, Greipp PR, et al A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007;21:529–534.
   PubMed Web of Science ®Google Scholar
• Velasco R, Petit J, Clapes V, Verdu E, Navarro X, Bruna J. Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients. J Peripher Nerv Syst 2010;15:17–25.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Frigeni B, Lanzani F, et al The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 2007;12:210–215.
   PubMed Web of Science ®Google Scholar
• Utecht KN, Kolesar J. Bortezomib: a novel chemotherapeutic agent for hematologic malignancies. Am J Health Syst Pharm 2008;65:1221–1231.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Xie W, Mitsiades C, et al Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009;27:3518–3525.
   PubMed Web of Science ®Google Scholar
• Cata JP, Weng HR, Burton AW, Villareal H, Giralt S, Dougherty PM. Quantitative sensory findings in patients with bortezomib-induced pain. J Pain 2007;8:296–306.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Gilardini A, Canta A, et al Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 2007;204:317–325.
   PubMed Web of Science ®Google Scholar
• Casafont I, Berciano MT, Lafarga M. Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons. Neurotox Res 2010;17:167–178.
   PubMed Web of Science ®Google Scholar
• Poruchynsky MS, Sackett DL, Robey RW, Ward Y, Annunziata C, Fojo T. Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. Cell Cycle 2008;7:940–949.
   PubMed Web of Science ®Google Scholar
• Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda, MD: National Cancer Institute; 2006.
   Google Scholar